Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Corcept Therapeutics (NQ: CORT ) 28.59 -0.38 (-1.31%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Corcept Therapeutics < Previous 1 2 3 4 5 6 7 Next > 6 Analysts Have This To Say About Corcept Therapeutics Today 15:00 EDT Via Benzinga Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know June 14, 2024 Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceuticals Inc. (NYSE: TEVA) has sued the company, accusing it of a monopoly... Via Benzinga Topics Lawsuit Exposures Financial Legal Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session June 14, 2024 Via Benzinga NASDAQ:CORT is not too expensive for the growth it is showing. May 31, 2024 NASDAQ:CORT is showing good growth, while it is not too expensive. Via Chartmill Corcept Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) May 29, 2024 Via Benzinga Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout. May 09, 2024 Exploring the Growth Potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as It Nears a Breakout. Via Chartmill 10 Health Care Stocks With Whale Alerts In Today's Session June 03, 2024 Via Benzinga Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome) June 03, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday May 28, 2024 Via Benzinga The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts May 02, 2024 Via Benzinga Recap: Corcept Therapeutics Q4 Earnings February 15, 2024 Via Benzinga Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session May 28, 2024 Via Benzinga Why Mid-Cap Corcept Therapeutics Stock Trading Higher On Tuesday? May 28, 2024 Corcept Therapeutics announced the GRACE Phase 3 trial results for relacorilant in Cushing's syndrome, showing significant improvements in hypertension and hyperglycemia. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session May 28, 2024 Via Benzinga Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome) May 28, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. May 10, 2024 Don't overlook CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—a stock with solid growth prospects and a reasonable valuation. Via Chartmill 10 Health Care Stocks With Whale Alerts In Today's Session May 09, 2024 Via Benzinga CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 01, 2024 CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update May 01, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Completes Enrollment in Phase 4 CATALYST Trial April 29, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call April 24, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter April 22, 2024 Insights from Corcept Therapeutics' Phase 3 GRACE trial results for endogenous Cushing's syndrome. Discover rapid improvements in hypertension and hyperglycemia without adverse effects. Join us for the... Via Benzinga Exposures Product Safety Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome April 22, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. April 19, 2024 For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering. Via Chartmill Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) April 15, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer April 08, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome April 01, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. March 29, 2024 In the world of growth stocks, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shines as a value proposition. Via Chartmill Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation. March 07, 2024 For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering. Via Chartmill What's Going On With Stress Hormone Modulator-Focused Corcept Therapeutics' Stock Friday? February 16, 2024 Findings of Corcept Therapeutics' CATALYST study on Cushing's syndrome & difficult-to-control type 2 diabetes. Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.